Latest From Recipharm AB
Opioid crisis gives US FDA something heparin crisis couldn’t: more drug recall authority in some cases. Meanwhile, Hanlim warning letter and Mercury Labs and Recipharm EU GMP non-compliance statements prove illuminating.
The latest biopharma industry appointments include a new chairman at Bone Therapeutics, chief executives at SOTIO and Helsinn Therapeutics, new CFOs at Sobi, AMRI and at Blade Therapeutics, and a new CMO at Vertex Pharmaceuticals.
This week’s roundup includes the appointment of Sanofi Genzyme’s executive vice president and various high-level appointments by companies including Recipharm, e-Therapeutics, Diplomat Pharmacy and Axovant.
Decades-long academic and pharma research to improve on the benefits of the 5-fluorouracil and Leucovorin combination in colorectal cancer has reached a crucial point, with a multinational Phase III pivotal trial of Isofol’s Modufolin being cleared by regulators but funding is still needed.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Recipharm AB
- Senior Management
Thomas Eldered, CEO
Bjorn Westberg, EVP/CFO
Kjell E Johansson, EVP/COO
Mark Quick, EVP Corp. Dev.
Jean-Francois Hilaire, Chief Strategy Officer
- Contact Info
Phone: 8 602 52 00
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.